Dr. Nigel Ramsden Joins Synthesis Med Chem USA As Head Of European Operations

Dr. Nigel Ramsden Joins Synthesis Med Chem USA As Head Of European Operations

 

Cambridge, UK, Shanghai, China & Melbourne, Australia – 20 November 2013 – SYNthesis med chem, the global contract research organisation providing synthetic and medicinal chemistry services, today announced that the company has appointed Dr Nigel Ramsden as Vice President of Medicinal Chemistry and Head of European Operations.

Based at SYNthesis' new facility at the Babraham Research Campus in Cambridge, UK, Nigel will act as Head of Medicinal Chemistry for the site, with responsibility for the management of medicinal and synthetic chemistry projects.

Prior to joining SYNthesis, Nigel was Head of Drug Discovery at Cellzome responsible for the progression of small molecule modulators of kinase and epigenetic targets. Before joining Cellzome in 2006, Nigel worked at GSK's Research labs in Stevenage, leading chemistry groups responsible for delivering numerous molecules into clinical trials.

Dr Ramsden commented:
"During my time at Cellzome I employed SYNthesis med chem as our major chemistry CRO and I was impressed by their ability to deliver complex synthetic routes to tight timelines and to impact on the design of molecules. When I was offered the opportunity to help with their development plans I was delighted to accept."

Professor Andrew Wilks, co-founder and Executive Chairman of SYNthesis, commented:
"I am delighted that Nigel has agreed to join SYNthesis med chem at such an exciting time in the company's development. He is an accomplished medicinal chemist with a formidable track record of delivering drug candidates. Under Nigel's guidance, the new laboratory in Cambridge will expand our medicinal chemistry capabilities in the UK, enabling SYNthesis to build upon the 'best of both worlds' strategy that has seen the company be so successful over such a short period of time."

About SYNthesis med chem

SYNthesis med chem is a global contract research organisation providing synthetic and medicinal services. Established in 2007, the company operates a unique, "best of both worlds" business model combining Western medicinal chemistry expertise with a cost effective and scalable synthetic chemistry capacity based in China.

Locally based medicinal chemistry expertise enables seamless SYNthesis/client communication as well as successful management of all chemistry projects. The company's medicinal chemists, based in Australia and the UK provide the design, innovation, creativity and problem solving expertise required to complement the skills and capabilities of the company's synthetic chemists. SYNthesis medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharmaceutical R&D pipeline. They also act as project managers for all custom synthesis and medicinal chemistry projects.

Issued for and on behalf of SYNthesis med chem by College Hill.

For further information please contact:
Simon Bury
Head of Business Development
E: [email protected]

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.